Provided by Tiger Trade Technology Pte. Ltd.

Apimeds Pharmaceutical U.S, Inc.

4.10
-0.9000-18.00%
Post-market: 4.04-0.0600-1.46%19:30 EDT
Volume:146.51K
Turnover:690.84K
Market Cap:6.19M
PE:-0.11
High:5.09
Open:4.90
Low:4.10
Close:5.00
52wk High:59.70
52wk Low:1.51
Shares:1.51M
Float Shares:725.94K
Volume Ratio:0.01
T/O Rate:20.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-38.5450
EPS(LYR):-0.1759
ROE:-144.99%
ROA:-69.29%
PB:0.76
PE(LYR):-23.31

Loading ...

Apimeds Pharmaceuticals Appoints Eric Sherb as New CFO

TIPRANKS
·
Yesterday

Apimeds Pharmaceuticals US - Appoints Eric Sherb as Chief Financial Officer Effective October 1, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

MindWave expands blockchain services into sports media markets

TIPRANKS
·
Sep 30

Apimeds Unit MindWave Innovations to Deploy MindChain Blockchain for AQUAEChain Platform

Reuters
·
Sep 30

Mindwave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate Flashchain for New York-Based Flash Sports & Media

THOMSON REUTERS
·
Sep 29

Mindwave Innovations: Parties Have not Publicly Disclosed Aggregate Dollar Value of Consideration Under Agreement.

THOMSON REUTERS
·
Sep 29

Amex Halt Add Info Lst 7.920000

THOMSON REUTERS
·
Sep 25

Top Midday Gainers

MT Newswires Live
·
Sep 25

Why Is Apimeds Pharmaceuticals US Stock (APUS) Up Today?

TIPRANKS
·
Sep 25

Mindwave Innovations Signs Agreement to Build and Operate Aquaechain, a Platform for Insured Alci Credits

THOMSON REUTERS
·
Sep 24

Apimeds Pharmaceuticals US - Enters First Amendment to Settlement Agreement on Sept 10, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 11

Apimeds Pharmaceuticals US - Board to Consist Solely of Four Members During Interim Period - SEC Filing

THOMSON REUTERS
·
Sep 11

Apimeds Pharmaceuticals US - Board to Expand to Seven Members After Interim Period - SEC Filing

THOMSON REUTERS
·
Sep 11

Apimeds Pharmaceuticals Adds Co-CEO Sungjoon Chae to Board

Reuters
·
Sep 11

Apimeds Pharmaceuticals US Enters Assignment and Transfer Agreement with Freet on August 19

Reuters
·
Aug 22

Apimeds Secures Key Apitox Rights via FreeT Agreement

TIPRANKS
·
Aug 22

Apimeds Pharmaceuticals US - Freet Assigns All Apitox-Related Rights to Apimeds Pharmaceuticals - SEC Filing

THOMSON REUTERS
·
Aug 22

Apimeds Pharmaceuticals US - Receives 100% Korean Clinic Rights, 25% U.S. Royalty, 25% Overseas Revenue Participation for Apitox - SEC Filing

THOMSON REUTERS
·
Aug 22

Apimeds Pharmaceuticals US Gains Apitox Rights in Assignment from South Korea’s FreeT

Reuters
·
Aug 22

Apimeds Net Loss Widens to $20.17 Million in Q2 2026; R&D Expenses Rise 47% to $959,742 vs Year-Ago Quarter

Reuters
·
Aug 15